BR112021020539A2 - Terminador de hélice tripla para trans-splicing de rna eficiente - Google Patents

Terminador de hélice tripla para trans-splicing de rna eficiente

Info

Publication number
BR112021020539A2
BR112021020539A2 BR112021020539A BR112021020539A BR112021020539A2 BR 112021020539 A2 BR112021020539 A2 BR 112021020539A2 BR 112021020539 A BR112021020539 A BR 112021020539A BR 112021020539 A BR112021020539 A BR 112021020539A BR 112021020539 A2 BR112021020539 A2 BR 112021020539A2
Authority
BR
Brazil
Prior art keywords
splicing
triple helix
terminator
trans
domain
Prior art date
Application number
BR112021020539A
Other languages
English (en)
Portuguese (pt)
Inventor
Jean Bennett
J Fisher Krishna
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BR112021020539A2 publication Critical patent/BR112021020539A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112021020539A 2019-04-17 2020-04-17 Terminador de hélice tripla para trans-splicing de rna eficiente BR112021020539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835164P 2019-04-17 2019-04-17
PCT/US2020/028797 WO2020214973A1 (en) 2019-04-17 2020-04-17 Triple helix terminator for efficient rna trans-splicing

Publications (1)

Publication Number Publication Date
BR112021020539A2 true BR112021020539A2 (pt) 2022-01-04

Family

ID=72837942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020539A BR112021020539A2 (pt) 2019-04-17 2020-04-17 Terminador de hélice tripla para trans-splicing de rna eficiente

Country Status (10)

Country Link
US (1) US20220204989A1 (enExample)
EP (1) EP3956442A4 (enExample)
JP (2) JP2022529065A (enExample)
KR (1) KR20220002910A (enExample)
CN (1) CN114040974B (enExample)
BR (1) BR112021020539A2 (enExample)
CA (1) CA3133555A1 (enExample)
IL (1) IL287243A (enExample)
MX (1) MX2021012702A (enExample)
WO (1) WO2020214973A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010959A (es) 2018-04-17 2021-01-15 Univ Pennsylvania Moleculas de empalme trans.
CN114040974B (zh) * 2019-04-17 2025-11-04 宾夕法尼亚州大学信托人 用于高效rna反式剪接的三螺旋终止子
AU2022259416A1 (en) * 2021-04-15 2023-11-16 Tacit Therapeutics, Inc. High efficiency trans-splicing for replacement of targeted rna sequences in human cells
IL311101A (en) 2021-09-03 2024-04-01 Tacit Therapeutics Inc RNA editing through recruitment of SPLICEOSOME components
WO2023205694A2 (en) * 2022-04-20 2023-10-26 Tacit Therapeutics, Inc. Stabilization of therapeutic trans-splicing rna molecules in human cells
US20250290067A1 (en) * 2022-05-03 2025-09-18 Tacit Therapeutics, Inc. Localization of trans-splicing nucleic acid molecules to and within the cellular nucleus
IL316944A (en) * 2022-05-13 2025-01-01 Ascidian Therapeutics Inc ABCA4 cross-linking molecules
EP4622662A1 (en) 2022-11-23 2025-10-01 Amber Bio Inc. Gene-modifying endonucleases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2151248A1 (en) * 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
CN104955951A (zh) * 2012-10-16 2015-09-30 麻省理工学院 稳定的非多腺苷酸化rna的产生
GB201219762D0 (en) * 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
EP2986635B1 (en) * 2013-04-18 2018-10-03 Fondazione Telethon Effective delivery of large genes by dual aav vectors
AU2016355343C1 (en) * 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
WO2019027869A1 (en) * 2017-07-31 2019-02-07 Massachusetts Institute Of Technology RNA-CLUSTER INDUCED TRANSCRIPT STABILIZER AND USES THEREOF
MX2020010959A (es) * 2018-04-17 2021-01-15 Univ Pennsylvania Moleculas de empalme trans.
CN114040974B (zh) * 2019-04-17 2025-11-04 宾夕法尼亚州大学信托人 用于高效rna反式剪接的三螺旋终止子

Also Published As

Publication number Publication date
MX2021012702A (es) 2022-01-24
CN114040974B (zh) 2025-11-04
JP2025121988A (ja) 2025-08-20
CA3133555A1 (en) 2020-10-22
US20220204989A1 (en) 2022-06-30
EP3956442A1 (en) 2022-02-23
IL287243A (en) 2021-12-01
JP2022529065A (ja) 2022-06-16
EP3956442A4 (en) 2023-01-25
AU2020260154A1 (en) 2021-11-11
WO2020214973A1 (en) 2020-10-22
CN114040974A (zh) 2022-02-11
KR20220002910A (ko) 2022-01-07

Similar Documents

Publication Publication Date Title
Vanier et al. Diagnostic tests for Niemann-Pick disease type C (NP-C): A critical review
BR112015012375A2 (pt) modificação e regulação de genoma à base de crispr
Miosge et al. Expression of collagen type I and type II in consecutive stages of human osteoarthritis
Poincloux et al. Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel
MX2021012702A (es) Terminador de triple hélice para un empalme trans de arn eficiente.
MX2020003339A (es) Arn guía de cpf1 modificado.
Schulz et al. Factors associated with confidence in fundoscopy
MX2022004657A (es) Secuenciacion de tejidos intactos a escala clinica e industrial.
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
BR112021018125A2 (pt) Métodos para gerar um molde de ácido nucleico de fita dupla de extremidade fechada assimétrico, para gerar um molde de ácido nucleico de fita dupla assimétrico a partir do dna tagmentado e de sequenciamento de dna tagmentado
Zhang et al. Increased nuclear stiffness via FAK-ERK1/2 signaling is necessary for synthetic mechano-growth factor E peptide-induced tenocyte migration
Salmina et al. Nucleolar aggresomes mediate release of pericentric heterochromatin and nuclear destruction of genotoxically treated cancer cells
Weng et al. Super-resolution imaging reveals TCTN2 depletion-induced IFT88 lumen leakage and ciliary weakening
Naito et al. Bicuspid aortopathy–molecular involvement of microRNAs and MMP-TIMP
Shim et al. Formamide denaturation of double-stranded DNA for fluorescence in situ hybridization (FISH) distorts nanoscale chromatin structure
Nguyen et al. The primary cilium is a self-adaptable, integrating nexus for mechanical stimuli and cellular signaling
EP3444351A4 (en) RIBONUCLEIC ACID PAPER WITH HARMFUL EFFECT ON NON-SMALL CELL LUNG CANCER AND PHARMACEUTICAL COMPOSITION THEREWITH
Berg et al. Transcription regulates bleb formation and stability independent of nuclear rigidity
MX2024007463A (es) Metodos para identificar y evaluar la inflamacion hepatica y la fibrosis hepatica en un sujeto mediante la determinacion de una puntuacion estratificada basada en la expresion genetica.
Williams et al. The condensation of HP1-α/Swi6 imparts nuclear stiffness
MX2020012480A (es) Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
Bicheng et al. Correction to: Evolution and hotspots of peer instruction: a visualized analysis using CiteSpace
Van den Boogaard et al. Acquisition of high quality DNA for massive parallel sequencing by in vivo chromatin immunoprecipitation
Al-Qarni Rote repetition in Saudi Arabian foreign language vocabulary acquisition.
WO2025064469A8 (en) Methods for assessing dosage for epigenetic modifying agents

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]